hagartech.com

What It Is

GWave is a non-invasive continuous glucose monitoring solution from HAGAR. It is not positioned as a traditional SaaS product, but rather as a combination of “medical hardware + app + cloud data services.” Its core selling point is the use of RF Wave radio-frequency waves to continuously measure blood glucose levels in real time, avoiding the pain and inconvenience of traditional finger-prick blood testing. The website says the device emits significantly less radiation than a smartphone, and uses proprietary AI algorithms to achieve miniaturization, cost efficiency, and high accuracy.

Core Features and Product Format

Based on the captured text, GWave consists of three main components: first, a non-invasive sensing device for continuous glucose measurement; second, a mobile app that connects to the device via Bluetooth, allowing users to check readings frequently on demand and receive automatic alerts when glucose levels fluctuate; and third, a cloud service for securely storing measurement data and relaying important information to caregivers and healthcare professionals. The website also states that it measures blood rather than interstitial fluid, and claims accuracy of over 95% compared with off-the-shelf finger-prick devices.

Pricing, Integrations, and Security

The website does not disclose plans, pricing, subscription models, purchase methods, or whether a trial is available, so its commercial availability and long-term cost of use cannot be assessed. There is also no information about third-party integrations, hospital system connectivity, APIs, or developer support. On the security side, it only mentions secure cloud storage, safe and reliable software, and news that GWave has received FDA Breakthrough Device Designation, but it does not provide specific compliance materials such as HIPAA, ISO, or SOC.

Pros, Cons, and Who It’s For

The main advantages are that it is non-invasive, continuous, real-time, supports alerts, and can share data with caregivers and healthcare professionals. It may be suitable for people with diabetes who need high-frequency monitoring, as well as family caregiving scenarios. The main weakness is limited disclosure: launch regions, regulatory progress, pricing, after-sales support, data compliance, and system integration are all unclear. For healthcare institutions or enterprise buyers, these gaps would make evaluation more difficult.

Access from China and Alternatives

Based on the available text, access, payment, and delivery conditions for mainland China cannot currently be determined, so china_access is marked as unknown. For use in China, key points to verify include whether it has obtained local medical device registration, whether the app and cloud services are available, cross-border data compliance, and after-sales channels. Comparable glucose monitoring solutions include Dexcom, Abbott FreeStyle Libre, Medtronic, as well as Chinese-market options such as Sinocare and SiBionics.